Compare AD & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AD | STVN |
|---|---|---|
| Founded | 1983 | 1949 |
| Country | United States | Italy |
| Employees | 4100 | N/A |
| Industry | Telecommunications Equipment | Containers/Packaging |
| Sector | Telecommunications | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | N/A | 2021 |
| Metric | AD | STVN |
|---|---|---|
| Price | $46.87 | $14.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $55.00 | $25.67 |
| AVG Volume (30 Days) | 165.8K | ★ 467.8K |
| Earning Date | 05-01-2026 | 03-04-2026 |
| Dividend Yield | ★ 73.21% | 0.43% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.67 |
| Revenue Next Year | N/A | $9.99 |
| P/E Ratio | $275.77 | ★ $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.03 | $13.91 |
| 52 Week High | $77.13 | $28.00 |
| Indicator | AD | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 43.98 |
| Support Level | $46.61 | $14.23 |
| Resistance Level | $50.23 | $16.69 |
| Average True Range (ATR) | 1.25 | 0.81 |
| MACD | -0.18 | 0.04 |
| Stochastic Oscillator | 31.05 | 16.59 |
Array Digital Infrastructure, formerly US Cellular, sold its regional wireless operations serving about 4.4 million customers to T-Mobile in August 2025. The firm has agreed to sell most of its remaining spectrum licenses to Verizon and AT&T; however, it will still retain rights to C-band spectrum in several locations after these deals are closed. Array also owns a 5.5% stake in Verizon Wireless' Los Angeles operations and about 4,400 wireless towers.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.